8 active not recruiting, 7 terminated, 3 recruiting, 1 completed. 10 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 4, Recruiting 3, Terminated 3 |
| Phase 2 | 8 | Terminated 4, Active not recruiting 3, Completed 1 |
Follow Pathologic Stage IIID Cutaneous Melanoma AJCC v8: new trials by email Literature Review of Pathologic Stage IIID Cutaneous Melanoma AJCC v8 trials Research Report on Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients Cyclophosphamide, Fludarabine, Lifileucel - Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Richard Wu | 2 | 2022-07-01 | 2026-02-24 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Active not recruiting | University of Southern California | 173 | 2021-11-24 | 2026-10-05 | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| Bone Loss in Melanoma Survivors Receiving Immunotherapy Biospecimen Collection, Dual X-ray Absorptiometry - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Terminated | M.D. Anderson Cancer Center | 12 | 2021-05-10 | 2025-08-17 | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 800 | 2021-02-21 | 2026-07-15 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Ipilimumab, Nivolumab, Patient Observation - Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 150 | 2021-02-09 | 2026-09-15 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Binimetinib, Nivolumab, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 3 | 2020-12-03 | 2024-12-04 |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery - Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-01-29 | 2024-10-30 |
| Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors Assessment, Biospecimen Collection, Quality-of-Life Assessment - Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8 | Active not recruiting | M.D. Anderson Cancer Center | 126 | 2019-12-05 | 2026-09-18 | |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Ipilimumab, Nivolumab, Prednisone - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2019-11-08 | 2026-10-14 |
| Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | Mayo Clinic | 12 | 2019-06-12 | 2026-01-28 |
| VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma Ipilimumab, Nivolumab, VX15/2503 - Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Emory University | 41 | 2018-12-13 | 2026-05-05 |
| Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Atezolizumab, Cobimetinib, Tiragolumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Completed | Mayo Clinic | 64 | 2018-10-05 | 2026-05-04 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies Capecitabine, Carboplatin, Cyclophosphamide - Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | M.D. Anderson Cancer Center | 221 | 2015-06-26 | 2025-06-04 |
Melanoma (12) · Lung Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Carcinoma, Renal Cell (2) · Fallopian Tube Neoplasms (2) · Neoplasm Metastasis (2) · Urinary Bladder Neoplasms (2) · Bone Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1) · Central Nervous System Neoplasms (1) · Chondrosarcoma (1)
Neoplasms (15) · Neoplasms by Site (15) · Neoplasms by Histologic Type (14) · Neoplasms, Germ Cell and Embryonal (13) · Neoplasms, Nerve Tissue (13) · Neuroectodermal Tumors (13) · Neuroendocrine Tumors (13) · Nevi and Melanomas (12) · Skin Diseases (12) · Skin Neoplasms (12) · Skin and Connective Tissue Diseases (12) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Urogenital Diseases (7) · Urogenital Neoplasms (6)
Nivolumab (8) · CTLA-4 Antigen (5) · Ipilimumab (5) · Disulfides (4) · Immunoglobulin G (4) · pembrolizumab (4) · Cyclophosphamide (3) · Paclitaxel (2) · Prednisone (2) · Taxes (2) · atezolizumab (2) · binimetinib (2) · deltacortene (2) · prednylidene (2) · Absorptiometry, Photon (1)
M.D. Anderson Cancer Center (8) · ECOG-ACRIN Cancer Research Group (2) · Mayo Clinic (2) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Richard Wu (1) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (19)
Aung Naing, MD (1) · Evan J Lipson (1) · Geoffrey T Gibney (1) · Joshua Veatch (1) · Kimberly Miller, PhD (1) · Leslie A Fecher (1) · Maryam Buni (1) · Matthew S. Block, M.D., Ph.D. (1) · Michael Lowe, MD, MA (1) · Noha Abdelwahab Hassan (1) · Philip McCarthy, MD (1) · Richard C Wu, M.D. Ph.D. (1) · Rodabe Amaria, MD (1) · Rodabe N Amaria (1) · Roger Lo, MD (1)
PMID 32503950, PMID 33909232, PMID 34562230, PMID 34825282, PMID 34965890, PMID 35537412, PMID 36821617, PMID 37129197, PMID 37328287, PMID 38252910, PMID 38365756, PMID 39816915, PMID 39945382, PMID 40234093, PMID 40580957
U10CA180820 (2), P30CA014089 (1), P30CA016056 (1), P30CA138292 (1), R01CA164333 (1), R37CA256867 (1), UM1CA186691 (1)